| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.14B | 6.11B | 5.87B | 5.38B | 5.19B | 4.90B |
| Gross Profit | 2.73B | 2.79B | 2.59B | 2.25B | 2.26B | 2.21B |
| EBITDA | 1.39B | 1.09B | 1.30B | 831.90M | 1.31B | 1.22B |
| Net Income | 782.50M | 585.30M | 755.60M | 413.90M | 827.50M | 785.90M |
Balance Sheet | ||||||
| Total Assets | 9.14B | 8.88B | 8.57B | 8.35B | 8.00B | 7.41B |
| Cash, Cash Equivalents and Short-Term Investments | 305.30M | 964.10M | 344.50M | 270.30M | 240.60M | 183.10M |
| Total Debt | 2.37B | 2.41B | 2.61B | 2.85B | 2.73B | 2.36B |
| Total Liabilities | 4.92B | 4.52B | 4.71B | 4.86B | 4.76B | 4.39B |
| Stockholders Equity | 4.22B | 4.36B | 3.86B | 3.49B | 3.23B | 3.02B |
Cash Flow | ||||||
| Free Cash Flow | 1.02B | 976.40M | 807.10M | 706.40M | 875.00M | 891.40M |
| Operating Cash Flow | 1.14B | 1.16B | 1.03B | 885.20M | 993.80M | 990.30M |
| Investing Cash Flow | -770.50M | -183.30M | -234.30M | -728.60M | -682.00M | -608.10M |
| Financing Cash Flow | -819.00M | -343.40M | -725.60M | -120.90M | -252.10M | -360.10M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | $337.96B | 21.11 | 31.90% | 2.92% | 1.23% | 17.97% | |
73 Outperform | $139.50B | 23.30 | 28.36% | 3.74% | -0.30% | -14.60% | |
72 Outperform | $21.71B | 28.47 | 18.59% | 1.38% | 1.45% | 42.04% | |
63 Neutral | $67.98B | 23.63 | 450.35% | 2.67% | -0.05% | 2.49% | |
62 Neutral | $20.33B | 14.63 | -3.31% | 3.23% | 1.93% | -12.26% | |
61 Neutral | $33.32B | 17.01 | 136.87% | 5.03% | -10.04% | -23.41% | |
55 Neutral | $13.57B | 17.43 | 4163.16% | 5.05% | -9.35% | 123.06% |
On December 9, 2025, Church & Dwight Co., Inc. announced a definitive agreement to sell its VitaFusion® and L’il Critters® brands to Piping Rock Health Products, Inc. This transaction, which includes related trademarks, licenses, and manufacturing facilities in Vancouver and Ridgefield, Washington, is expected to close by the end of the year, subject to customary conditions. The sale is part of a strategic review of the company’s vitamin, minerals, and supplement business, which represents less than 5% of its anticipated 2025 net sales. Church & Dwight anticipates a one-time, after-tax charge of $40 million to $45 million in the fourth quarter of 2025 due to this transaction. The sale is expected to strengthen the company’s portfolio and allow a greater focus on its remaining power brands.
The most recent analyst rating on (CHD) stock is a Buy with a $102.00 price target. To see the full list of analyst forecasts on Church & Dwight stock, see the CHD Stock Forecast page.
On December 4, 2025, Church & Dwight Co., Inc.’s Board of Directors approved an amendment to their Corporate Governance Guidelines, removing the limits on the number of years a Board member may serve. This change aligns with the practices of many of its peers and most of the S&P 500, aiming to balance board refreshment with continuity and experience by evaluating tenure on a case-by-case basis.
The most recent analyst rating on (CHD) stock is a Buy with a $102.00 price target. To see the full list of analyst forecasts on Church & Dwight stock, see the CHD Stock Forecast page.